AstraZeneca Iressa Link To Interstitial Lung Disease Questioned In Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Iressa’s link to interstitial lung disease is uncertain given the similar rate of ILD seen in patients receiving the AstraZeneca drug and placebo, FDA Office of Drug Evaluation I Director Robert Temple, MD, states in a "Feb. 19 review memo.
You may also be interested in...
Iressa Clinical Development Timeline
Chronicle of the development and review of AstraZeneca’s tyrosine kinase inhibitor gefitinib for EGFR mutation-positive non-small cell lung cancer.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product